30 January 2024 (Tuesday) - Stem Cell Evidence Alert Update

The nice people at the Stem Cell Evidence Alert sent their update today… This is the sort of thing that I keep hearing that I should be reading as CPD… for all that it is rather interesting, it’s not practically improving what I do on a daily basis

ARTICLE OF THE MONTH Prospective Multi-Institutional Study of Eculizumab to Treat High-Risk Stem Cell Transplant Associated TMA. Jodele, S., et al. (2023) Blood [record in progress] PICO SUMMARY +++++ TOP ARTICLES Peripheral Blood Haploidentical Allogeneic Stem Cell Transplantation in Older Adults with Acute Myeloid Leukemia and Myelodysplastic Syndromes Demonstrates Long Term Survival, Results from the Australasian Bone Marrow Transplant Recipient Registry. Abadir, E., et al. (2023) Transplantation and Cellular Therapy [record in progress] Fludarabine melphalan versus fludarabine treosulfan for reduced intensity conditioning regimen in allogeneic hematopoietic stem cell transplantation: a retrospective analysis. Chichra, A., et al. (2023) International Journal of Hematology [record in progress] . Reconstitution of Natural Killer cells after allogeneic hematopoietic stem cell transplantation is facilitated by Huiyang-Guben decoction through activating the Smad7/Stat3 signal pathway. Gao, X., et al. (2023) Molecular and Cellular Biochemistry [record in progress] Prevention of CMV/EBV reactivation by double-specific T cells in patients after allogeneic stem cell transplantation: results from the randomized phase I/IIa MULTIVIR-01 study. Gerbitz, A., et al. (2023) Frontiers in Immunology 14:1251593 Peripheral blood haploidentical hematopoietic cell transplantation for patients aged 70 years and over with acute myeloid leukemia or high-risk myelodysplastic syndrome. Harbi, S., et al. (2023) Bone Marrow Transplantation [record in progress] Chronic graft-versus-host disease is characterized by high levels and distinctive tissue-of-origin patterns of cell-free DNA. Pang, Y., et al. (2023) iScience 26:108160 Assessment of monocytic-myeloid-derived suppressive cells (M-MDSC) before and after allogeneic hematopoietic stem cell transplantation in acute leukemia patients. Peterlin, P., et al. (2023) EJHaem 4 (4):1089-1095 Diverse macrophage populations contribute to distinct manifestations of human cutaneous graft-versus-host disease. Strobl, J., et al. (2023) The British Journal of Dermatology [record in progress] Prophylactic versus Preemptive modified donor lymphocyte infusion for high-risk acute leukemia after allogeneic hematopoietic stem cell transplantation: a multicenter retrospective study. Yang, L., et al. (2023) Bone Marrow Transplantation [record in progress]

22 December 2023 (Friday) - Stem Cell Evidence Alert

The Stem Cell Evidence Alert update arrived in my in-box today. There was quite a bit of talk about allogenic stem cell transplants. Back in the day we used to do quite a few of those… but they don’t seem to be anywhere near as common these days.

Perhaps it is a “specialist centre” thing and not something done is the district general hospitals any more?

 

ARTICLE OF THE MONTH Prospective Multi-Institutional Study of Eculizumab to Treat High-Risk Stem Cell Transplant Associated TMA. Jodele, S., et al. (2023) Blood [record in progress] PICO SUMMARY +++++

TOP ARTICLES Peripheral Blood Haploidentical Allogeneic Stem Cell Transplantation in Older Adults with Acute Myeloid Leukemia and Myelodysplastic Syndromes Demonstrates Long Term Survival, Results from the Australasian Bone Marrow Transplant Recipient Registry. Abadir, E., et al. (2023) Transplantation and Cellular Therapy [record in progress] Fludarabine melphalan versus fludarabine treosulfan for reduced intensity conditioning regimen in allogeneic hematopoietic stem cell transplantation: a retrospective analysis. Chichra, A., et al. (2023) International Journal of Hematology [record in progress] . Reconstitution of Natural Killer cells after allogeneic hematopoietic stem cell transplantation is facilitated by Huiyang-Guben decoction through activating the Smad7/Stat3 signal pathway. Gao, X., et al. (2023) Molecular and Cellular Biochemistry [record in progress] Prevention of CMV/EBV reactivation by double-specific T cells in patients after allogeneic stem cell transplantation: results from the randomized phase I/IIa MULTIVIR-01 study. Gerbitz, A., et al. (2023) Frontiers in Immunology 14:1251593 Peripheral blood haploidentical hematopoietic cell transplantation for patients aged 70 years and over with acute myeloid leukemia or high-risk myelodysplastic syndrome. Harbi, S., et al. (2023) Bone Marrow Transplantation [record in progress] Chronic graft-versus-host disease is characterized by high levels and distinctive tissue-of-origin patterns of cell-free DNA. Pang, Y., et al. (2023) iScience 26:108160 Assessment of monocytic-myeloid-derived suppressive cells (M-MDSC) before and after allogeneic hematopoietic stem cell transplantation in acute leukemia patients. Peterlin, P., et al. (2023) EJHaem 4 (4):1089-1095 Diverse macrophage populations contribute to distinct manifestations of human cutaneous graft-versus-host disease. Strobl, J., et al. (2023) The British Journal of Dermatology [record in progress] Prophylactic versus Preemptive modified donor lymphocyte infusion for high-risk acute leukemia after allogeneic hematopoietic stem cell transplantation: a multicenter retrospective study. Yang, L., et al. (2023) Bone Marrow Transplantation [record in progress] +++++

31 may 2022 (Tuesday) - Stem Cell Evidence Alert

The monthly Stem Cell Evidence Alert came today. I haven’t mentioned this one for a while, but one or two of the articles referring to bone marrow transplants were enlightening.

ARTICLE OF THE MONTH In-vivo T-cell depleted reduced-intensity conditioned allogeneic haematopoietic stem-cell transplantation for patients with acute lymphoblastic leukaemia in first remission: results from the prospective, single-arm evaluation of the UKALL14 trial. Marks, D.I., et al. (2022) The Lancet. Haematology.  9(4):e276-e288. PICO SUMMARY +++++

SELECTED ARTICLES

Hematopoietic stem cell transplantation for adolescents and adults with inborn errors of immunity, an EBMT IEWP study. 
Albert, M. H., et al. (2022) Blood [record in progress]

Myeloablative conditioning with thiotepa-busulfan-fludarabine does not improve the outcome of patients transplanted with active leukemia: final results of the GITMO prospective trial GANDALF-01.
Bonifazi, F. et al. (2022) Bone Marrow Transplantation [record in progress]

Adding bendamustine to melphalan before ASCT improves CR rate in myeloma vs. melphalan alone: A randomized phase-2 trial.
Farag, S., et al. (2022) Bone Marrow Transplantation [record in progress]

Neutralizing antibody and T cell responses to SARS-CoV-2 vaccination in hematopoietic cell transplant recipients.
Gavriilaki, E., et al. (2022) Bone Marrow Transplantation [record in progress]

Feasibility and efficacy of partially replacing post-transplant cyclophosphamide with bendamustine in pediatric and young adult patients undergoing haploidentical bone marrow transplantation
Katsanis, E., et al. (2022) Transplantation and Cellular Therapy [record in progress]

Narsoplimab, a Mannan-Binding Lectin-Associated Serine Protease-2 Inhibitor, for the Treatment of Adult Hematopoietic Stem-Cell Transplantation-Associated Thrombotic Microangiopathy.
Khaled, S. K., et al. (2022) Journal of Clinical Oncology: Jco2102389.

Busulfan, Melphalan, and Etoposide (BuMe) Showed an Equivalent Effect to Busulfan, Cyclophosphamide, and Etoposide (BuCE) as Conditioning Therapy for Autologous Stem Cell Transplantation in Patients with Relapsed or High Risk Non-Hodgkin's Lymphoma: A Multicenter Randomized Phase II Study by the Consortium for Improving Survival of Lymphoma (CISL).
Kim, K.H., et al. (2022) Cancer Research and Treatment [record in progress]

Mesenchymal Stromal Cells for Treating Steroid-Resistant Acute and Chronic Graft Versus Host Disease: A Multicenter Compassionate Use Experience.
Macías-Sánchez, M. D. M., et al. (2022) Stem Cell Translational Medicine [record in progress]

Evaluation of the pharmacokinetic interaction between letermovir and tacrolimus in allogeneic hematopoietic cell transplant recipients.
Marciano, K. A., et al. (2022) Transplantation and Cellular Therapy [record in progress]

20 January 2022 (Thursday) - Stem Cell Evidence Alert

Well… I’m sitting at home on sick leave after having had a large lump cut out of my sinuses and I’m not feeling on top for, That’s the reason that I’m giving for why none of this seems to make much sense to me…

 

SELECTED ARTICLES

Comparison of Outcomes After Second Allogeneic Hematopoietic Cell Transplantation Versus Donor Lymphocyte Infusion in Allogeneic Hematopoietic Cell Transplant Patients.
Al-Shaibani, E., et al. (2021) Clinical Lymphoma, Myeloma and Leukemia [record in progress]

Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma.
Bishop, M. R., et al. (2021) The New England Journal of Medicine [record in progress]

Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma.
Costa, L. J., et al (2021) Journal of Clinical Oncology: Jco2101935

Impact of donor-derived CD34+ infused cell dose on outcomes of patients undergoing allo-HCT following reduced intensity regimen for myelofibrosis: a study from the Chronic Malignancies Working Party of the EBMT.
Czerw, T., et al. (2021) Bone Marrow Transplantation [record in progress]

Safety and efficacy of prophylactic levofloxacin in pediatric and adult hematopoietic stem cell transplant patients.
Gardner, J. C., et al. (2021) Transplantation and Cellular Therapy [record in progress]

A decision analysis for unrelated bone marrow transplantation or immediate cord blood transplantation for patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first complete remission: Unrelated BMT or immediate CBT for Ph-negative ALL.
Kako, S., et al. (2021) Transplantation and Cellular Therapy [record in progress]

Graft-Versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide versus Cyclosporine A and Methotrexate in Matched Sibling Donor Transplantation.
Nagler, A., et al. (2021) Transplantation and Cellular Therapy [record in progress]

ATG and Post-transplant Cyclophosphamide predisposes to inferior outcome when using cryopreserved stem cell grafts.
Novitzky-Basso, L., et al. (2021) European Journal of Haematology [record in progress]

Cytokine Release Syndrome Following Peripheral Blood Stem Cell Haploidentical HCT with Post-Transplant Cyclophosphamide: CRS post haploidentical HCT with PTCy.
Outoukesh, S., et al. (2021) Transplantation and Cellular Therapy [record in progress]
 

ARTICLE OF THE MONTH Randomized Phase III BMT CTN Trial of Calcineurin Inhibitor-Free Chronic Graft-Versus-Host Disease Interventions in Myeloablative Hematopoietic Cell Transplantation for Hematologic Malignancies. Luznik, L., et al. (2021) Journal of Clinical Oncology: Jco2102293 PICO SUMMARY +++++